RNAC Q2 2022 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$39M+99.7% YoY

Gross Profit

$39M98.7% margin

Operating Income

$14M35.3% margin

Net Income

$9M21.9% margin

EPS (Diluted)

$1.74

QoQ Revenue Growth

+15.5%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$188M

Total Liabilities

$98M

Stockholders' Equity

$90M

Cash & Equivalents

$138M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$39M	$20M	+99.7%
Gross Profit	$39M	$20M	+97.2%
Operating Income	$14M	$452,000	+2966.4%
Net Income	$9M	$5M	+88.4%